The identified genes, including SEMA3D and PDE1A, may serve as potential diagnostic biomarkers for differentiating between CD and UC, as well as therapeutic targets for restoring enteric dysautonomia and SMC proliferative disorders in CD. This evidence concerns the gene SEMA3D and dysautonomia.